PubMed
Peptide bioregulators and liver function in aging models
Khavinson et al., 2012
Ovarian Bioregulator
Investigational peptide-bioregulator discussed for ovarian/endocrine pathways.
Overall check-ins
Trackers & reports
Overview
Investigational peptide-bioregulator discussed for ovarian/endocrine pathways.
Community
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 0% · Mixed 50% · Unfavorable overall 50%
Benefits users selected when logging a favorable or mixed check-in.
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 2 to ≥ 2 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Research
PubMed
Khavinson et al., 2012
PubMed
Khavinson, 2009
Tools
More ways to learn about Ovagen from observational PeptIQ data.
Compare with
Related peptides
Help
This page summarizes 6 anonymized self-reports from PeptIQ users who track Ovagen, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
This wiki does not assess safety or recommend use. Ovagen is listed as Research Only. Consult a licensed clinician for personal medical decisions.
Research, primarily in animal models, suggests Ovagen may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceOvagen is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Ovagen as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceThe safety and effectiveness of Ovagen have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhile there are over 200 published studies on Ovagen, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source